This addition to Biomica’s scientific expertise will support the company’s upcoming steps in its immuno-oncology clinical development program
Rehovot, Israel – July 28, 2022 – Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
REHOVOT, Israel, July 26, 2022 – Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that the first patient was dosed in its Phase I clinical trial that is designed primarily to evaluate the safety and tolerability of Biomica’s microbiome-based immuno-oncology drug candidate,
Proof of Concept (POC) in-human trial to take place at Rambam Health Care Campus in Israel throughout 2022
REHOVOT, Israel, July 11, 2022. Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
Rehovot, Israel – July 5, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced it will be presenting at Microbiome Connect Europe taking place between July 6-7, 2022, in Amsterdam,
Dr. Elran Haber to participate in the Industry Leaders opening panel at this premier Microbiome conference
Rehovot, Israel – June 15, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics,
Rehovot, Israel – May 23, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced it will be presenting at the 2022 ASCO Annual Meeting, a conference taking place in Chicago,
Rehovot, Israel – May 16, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced it will be presenting at the Digestive Disease Week (DDW 2022) Conference taking place May 21-24,
The research will be focused on developing new treatments for Inflammatory Bowel Disease (IBD)
Rehovot, Israel – April 13, 2022 – Biomica Ltd. (Biomica), an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
Clearance for Proof-of-Concept Phase I human trial in oncology received from Israeli Ministry of Health
Rehovot, Israel – January 11, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
The results demonstrate the efficacy of Biomica’s live bacterial consortia, BMC333, for the treatment of IBD
Rehovot, Israel – November 30, 2021 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.